Literature DB >> 16546053

Paediatric rheumatology--a global perspective.

Sujata Sawhney1, Claudia Saad Magalhães.   

Abstract

This chapter aims to give a global perspective to paediatric rheumatology. The main points covered are the incidence, recognition of paediatric autoimmune diseases, and ethnic/geographic distribution. The most prevalent disease is juvenile idiopathic arthritis; robust data are still required for childhood-onset systemic lupus erythematosus, dermatomyositis, and scleroderma. Mimicking or overlapping infections are a major challenge in developing countries, and immunization policies in our patients in these areas need specific attention. The delivery of paediatric rheumatology care is also overviewed. Discrepancies in health-care resources and priorities are found in developing countries. Although most anti-rheumatic treatments are available worldwide, they are prohibitively expensive in many countries. For more traditional anti-rheumatic drugs there is still an ongoing need for good core outcome data across the world to ensure valid comparisons. Parent/patient education has been implemented worldwide in paediatric rheumatology through the power of the Internet. Physician and undergraduate training goals must be met to facilitate competent musculoskeletal assessment, a proper understanding of age-dependent variations, diagnosis, referral to specialists, and improved standards of care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546053     DOI: 10.1016/j.berh.2005.11.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  10 in total

Review 1.  JIA in 2011: New takes on categorization and treatment.

Authors:  Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2012-01-10       Impact factor: 20.543

2.  Pediatric rheumatology in Southeast Asia: insights from the Singapore experience.

Authors:  Thaschawee Arkachaisri
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

Review 3.  Cyclosporine for Systemic Onset Juvenile Idiopathic Arthritis: Current Stand and Future Directions.

Authors:  Narendra Kumar Bagri
Journal:  Indian J Pediatr       Date:  2019-06-01       Impact factor: 1.967

4.  Chronic inflammatory arthritis prevalence estimates for children and adolescents in three Canadian provinces.

Authors:  Natalie Jane Shiff; Lisa M Lix; Kiem Oen; Lawrence Joseph; Ciaran Duffy; Elizabeth Stringer; Lori B Tucker; Lawrence W Svenson; Patrick Belisle; Sasha Bernatsky
Journal:  Rheumatol Int       Date:  2014-07-15       Impact factor: 2.631

Review 5.  Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Authors:  Elizabeth D Mellins; Claudia Macaubas; Alexei A Grom
Journal:  Nat Rev Rheumatol       Date:  2011-06-07       Impact factor: 20.543

Review 6.  Oligoarticular and polyarticular JIA: epidemiology and pathogenesis.

Authors:  Claudia Macaubas; Khoa Nguyen; Diana Milojevic; Jane L Park; Elizabeth D Mellins
Journal:  Nat Rev Rheumatol       Date:  2009-10-06       Impact factor: 20.543

Review 7.  Progress made towards enhancement of rheumatology education and practice in Zambia: review of an ILAR-supported project.

Authors:  James Chipeta; Panganani Njobvu; Paul E McGill; Richard Bucala
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

Review 8.  Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.

Authors:  Sriharsha Grevich; Susan Shenoi
Journal:  Adolesc Health Med Ther       Date:  2017-11-09

9.  Spectrum of paediatric rheumatic diseases in Nigeria.

Authors:  Babatunde Hakeem Olaosebikan; Olufemi Oladipo Adelowo; Barakat Adeola Animashaun; Richard Oluyinka Akintayo
Journal:  Pediatr Rheumatol Online J       Date:  2017-01-31       Impact factor: 3.054

Review 10.  The human microbiome and juvenile idiopathic arthritis.

Authors:  Anouk Verwoerd; Nienke M Ter Haar; Sytze de Roock; Sebastiaan J Vastert; Debby Bogaert
Journal:  Pediatr Rheumatol Online J       Date:  2016-09-20       Impact factor: 3.054

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.